Lesanne Life Sciences

Lesanne Life Sciences was an Australian biotechnology company specializing in the discovery and development of novel Adeno-associated virus (AAV) vectors for gene therapy. The company utilized advanced capsid engineering and directed evolution technologies to create optimized viral vectors with improved tissue specificity, enhanced potency, and reduced immunogenicity. Founded by Dr. Leszek Lisowski, a leading expert in vectorology, the firm focused on overcoming the delivery challenges associated with first-generation gene therapies. In 2014, Lesanne Life Sciences was acquired by 4D Molecular Therapeutics (4DMT), integrating its proprietary AAV discovery platform into 4DMT's Therapeutic Vector Evolution engine. The acquisition significantly expanded 4DMT's intellectual property and capabilities in targeted gene delivery.